NCT02279641View on ClinicalTrials.gov

RDEA3170 and Allopurinol Combination Study in Gout Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 1, 2014

Primary Completion Date

April 6, 2015

Study Completion Date

September 11, 2015

Conditions
Gout
Interventions
DRUG

RDEA3170 10 mg

DRUG

allopurinol 300 mg

Trial Locations (1)

66212

Overland Park

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT02279641 - RDEA3170 and Allopurinol Combination Study in Gout Subjects | Biotech Hunter | Biotech Hunter